RecruitingNot ApplicableNCT06546592

Locally Optimised Contouring With AI Technology for Radiotherapy

LOCATOR - Locally Optimised Contouring With AI Technology for Radiotherapy


Sponsor

Royal North Shore Hospital

Enrollment

444 participants

Start Date

Feb 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

LOCATOR is a multicentre phase II randomised clinical trial that is looking at the process of contouring in radiation treatment for breast cancer patients. This study looks at whether contouring aided by artificial intelligence (AI) is comparable in quality to that of contouring done completely manually by a radiation oncologist. We are also looking at whether AI assisted contouring saves radiation oncologists time when compared to fully manual contouring. LOCATOR uses the LOCATOR software which is an in-house software developed locally and trained on local data.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • years and older who are planned for primary breast malignancy
  • ECOG performance 0-2
  • Ability to understand and willingness to sign a written informed consent document
  • The target volume must be able to be objectively reviewed by current published national or international clinical guidelines

Exclusion Criteria2

  • Patients under 18 years of age
  • Patients unable to understand consent documents

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAI assisted contouring

Initial are generated automatically using software powered by artificial intelligence


Locations(3)

Western Cancer Centre Dubbo

Dubbo, New South Wales, Australia

Central West Cancer Centre

Orange, New South Wales, Australia

Department of Radiation Oncology, Royal North Shore Hospital

St Leonards, New South Wales, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06546592


Related Trials